Applied DNA to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th – 30th from 9:00 a.m. – 5:00 p.m. EDT

Applied DNA to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th – 30th from 9:00 a.m. – 5:00 p.m. EDT
CANNANNEW REPORT

STONY BROOK, N.Y.–(BUSINESS WIRE)–$APDN #LinearDNA—Applied DNA Sciences, Inc. (NASDAQ: APDN), a leader in cell-free, enzymatic DNA production, today announced that CEO Dr. James A. Hayward is invited to present at the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest, on March 28th – 30th from 9:00 a.m. – 5:00 p.m. EDT. Dr. Hayward’s presentation will be available on-demand for the duration of the conference via the sign-up link: Sign up here to access the presentation During the virtual conference, investors will hear from executives from a wide range of sectors, including Biotech, Clean Energy, Electric Vehicles, Financial Services, Fintech & REITs, Gaming & Entertainment, Healthcare, Healthcare IT, Infrastructure, Shipping and Technology/Media/Telecom. The conference will feature company presentations, fireside chats, roundtable discussions, and live Q&A with CEOs moderated by Maxim Research Analysts. This conference will be live on M-Vest. To attend, sign up to become an M-Vest member: Click Here to Reserve your seat About Applied DNA Sciences Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction (“PCR”)-based manufacturing platform that allows for the large-scale cell-free production of specific DNA sequences. The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR T therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others. Leveraging its deep expertise in nucleic acid-based technologies, the Company…

Excerpt only …
READ MORE BELOW
Source : Applied DNA to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th – 30th from 9:00 a.m. – 5:00 p.m. EDT

reposted by Cannabis News World

This site uses Akismet to reduce spam. Learn how your comment data is processed.